Indeed, after 24 weeks of treatment with 18 mg and 6 mg of selonsertib, a selective inhibitor of ASK1, 43% and 30% of patients with nonalcoholic steatohepatitis and stage 2 or 3 liver fibrosis, respectively, experienced one or more stage reduction in liver fibrosis (Loomba et al., 2018b), compared with 20% of patients receiving an inactive therapy (simtuzumab). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.